<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31362993</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>78</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of the rheumatic diseases</Title>
          <ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.</ArticleTitle>
        <Pagination>
          <StartPage>1454</StartPage>
          <EndPage>1462</EndPage>
          <MedlinePgn>1454-1462</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2019-215764</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">In SELECT-COMPARE, a randomised double-blind study, upadacitinib 15 mg once daily was superior to placebo or adalimumab on background methotrexate (MTX) for treating rheumatoid arthritis signs and symptoms and inhibited radiographical progression versus placebo at 26 weeks. Here we report 48-week safety and efficacy in patients who continued their original medication or were rescued to the alternative medication for insufficient response.</AbstractText>
          <AbstractText Label="METHODS">Patients on MTX received upadacitinib 15 mg, placebo or adalimumab for 48 weeks. Rescue without washout, from placebo or adalimumab to upadacitinib or upadacitinib to adalimumab occurred if patients had &lt;20% improvement in tender joint count (TJC) or swollen joint count (SJC) (weeks 14/18/22) or Clinical Disease Activity Index (CDAI) &gt;10 (week 26); remaining placebo patients were switched to upadacitinib at week 26. Efficacy was analysed by randomised group (non-responder imputation), as well as separately for rescued patients (as observed). Treatment-emergent adverse events per 100 patient-years were summarised.</AbstractText>
          <AbstractText Label="RESULTS">Consistent with responses through week 26, from weeks 26 to 48, responses by randomised group including low disease activity, clinical remission and improvements in pain and function remained superior for upadacitinib versus adalimumab; radiographical progression remained lower for upadacitinib versus placebo (linear extrapolation). Although both switch groups responded, a higher proportion of patients rescued to upadacitinib from adalimumab achieved CDAI ≤10 at 6 months postswitch versus patients rescued from upadacitinib to adalimumab. Safety at week 48 was comparable to week 26.</AbstractText>
          <AbstractText Label="CONCLUSION">Upadacitinib+MTX demonstrated superior clinical and functional responses versus adalimumab+MTX and maintained inhibition of structural damage versus placebo+MTX through week 48. Patients with an insufficient response to adalimumab or upadacitinib safely achieved clinically meaningful responses after switching to the alternative medication without washout.</AbstractText>
          <CopyrightInformation>© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fleischmann</LastName>
            <ForeName>Roy M</ForeName>
            <Initials>RM</Initials>
            <AffiliationInfo>
              <Affiliation>Medicine, University of Texas Southwestern, Dallas, Texas, USA rfleischmann@arthdocs.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Genovese</LastName>
            <ForeName>Mark C</ForeName>
            <Initials>MC</Initials>
            <Identifier Source="ORCID">0000-0001-5294-4503</Identifier>
            <AffiliationInfo>
              <Affiliation>Rheumatology, Stanford University, Palo Alto, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Enejosa</LastName>
            <ForeName>Jeffrey V</ForeName>
            <Initials>JV</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Clinical Development, Abbvie Inc, North Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mysler</LastName>
            <ForeName>Eduardo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Organización Medica de Investigación, Buenos Aires, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bessette</LastName>
            <ForeName>Louis</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Universite Laval Faculte de medecine, Quebec City, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Centre de recherche du CHU de Québec, Université Laval, Quebec City, Québec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peterfy</LastName>
            <ForeName>Charles</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Spire Sciences Inc, Boca Raton, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durez</LastName>
            <ForeName>Patrick</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Pôle de Recherche en Rhumatologie, Institut de Recherche Experimentale et Clinique, Universitde Louvain, UCL, Brussels, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ostor</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cabrini Medical Center, Malvern, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yihan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Data and Statistical Sciences, AbbVie Inc, North Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Song</LastName>
            <ForeName>In-Ho</ForeName>
            <Initials>IH</Initials>
            <AffiliationInfo>
              <Affiliation>Immunology Clinical Development, Abbvie Inc, North Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02629159</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>07</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Rheum Dis</MedlineTA>
        <NlmUniqueID>0372355</NlmUniqueID>
        <ISSNLinking>0003-4967</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006575">Heterocyclic Compounds, 3-Ring</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4RA0KN46E0</RegistryNumber>
          <NameOfSubstance UI="C000613732">upadacitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>FYS6T7F842</RegistryNumber>
          <NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
          <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006575" MajorTopicYN="N">Heterocyclic Compounds, 3-Ring</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">dmards (biologic)</Keyword>
        <Keyword MajorTopicYN="Y">dmards (synthetic)</Keyword>
        <Keyword MajorTopicYN="Y">methotrexate</Keyword>
        <Keyword MajorTopicYN="Y">rheumatoid arthritis</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: RF has received research grants and consulting fees from AbbVie, Eli Lilly, and Pfizer. MG has served as a consultant for, and has received grants from, AbbVie, Eli Lilly, Pfizer, Galapagos, and Gilead. EM has received research grants and consulting fees from AbbVie, Eli Lilly, Pfizer, Roche, BMS, and Sandoz. LB has served as a speaker on behalf of, and received consulting fees and research grants from, Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly and Novartis. CP is an employee and shareholder of Spire Sciences, has served as a speaker on behalf of Amgen, Bristol-Myers Squibb and has served as a consultant for Centrexion, Crescendo Bioscience, Daiichi Sankyo, EMD Serono, Five Prime, Flexion Therapeutics, Genentech, Gilead, GlaxoSmithKline, Pfizer, Plexikkon, Regeneron, Roche and SetPoint. PD has received speaker fees from BMS, Sanofi, Eli Lilly, and Celltrion. AO has served as a speaker on behalf of, and has received consulting fees and/or research grants from BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Eli Lilly and Novartis. JVE, YL, and I-HS are employees of AbbVie and may own stock or stock options.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31362993</ArticleId>
        <ArticleId IdType="pmc">PMC6837258</ArticleId>
        <ArticleId IdType="doi">10.1136/annrheumdis-2019-215764</ArticleId>
        <ArticleId IdType="pii">annrheumdis-2019-215764</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Smolen JS, Breedveld FC, Burmester GR, et al. . 
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international Task force. Ann Rheum Dis
2016;75:3–15. 10.1136/annrheumdis-2015-207524
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2015-207524</ArticleId>
            <ArticleId IdType="pmc">PMC4717393</ArticleId>
            <ArticleId IdType="pubmed">25969430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grigor C, Capell H, Stirling A, et al. . 
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. The Lancet
2004;364:263–9. 10.1016/S0140-6736(04)16676-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(04)16676-2</ArticleId>
            <ArticleId IdType="pubmed">15262104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Versteeg GA, Steunebrink LMM, Vonkeman HE, et al. . 
Long-Term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice. Clin Rheumatol
2018;37:1189–97. 10.1007/s10067-017-3962-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10067-017-3962-5</ArticleId>
            <ArticleId IdType="pmc">PMC5913385</ArticleId>
            <ArticleId IdType="pubmed">29388086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smolen JS, Landewé R, Bijlsma J, et al. . 
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis
2017;76:960–77. 10.1136/annrheumdis-2016-210715
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2016-210715</ArticleId>
            <ArticleId IdType="pubmed">28264816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh JA, Saag KG, Bridges SL, et al. . 
2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol
2016;68:1–26. 10.1002/art.39480
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.39480</ArticleId>
            <ArticleId IdType="pubmed">26545940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burmester GR, Kremer JM, Van den Bosch F, et al. . 
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet
2018;391:2503–12. 10.1016/S0140-6736(18)31115-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)31115-2</ArticleId>
            <ArticleId IdType="pubmed">29908669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Genovese MC, Fleischmann R, Combe B, et al. . 
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. The Lancet
2018;391:2513–24. 10.1016/S0140-6736(18)31116-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)31116-4</ArticleId>
            <ArticleId IdType="pubmed">29908670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smolen JS, Pangan AL, Emery P, et al. . 
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. The Lancet
2019;393:2303–11. 10.1016/S0140-6736(19)30419-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)30419-2</ArticleId>
            <ArticleId IdType="pubmed">31130260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Vollenhoven RTT, Pangan AL, Friedman A, et al. . 
A phase 3, randomized, double-blind study comparing Upadacitinib monotherapy to MTX monotherapy in MTX-Naïve patients with active rheumatoid arthritis. Arthritis and Rheumatology
2018.</Citation>
        </Reference>
        <Reference>
          <Citation>
Fleischmann R, Pangan AL, Song In‐Ho, et al. . 
Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, Double‐Blind, randomized controlled trial. Arthritis Rheumatol
2019. 
10.1002/art.41032
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41032</ArticleId>
            <ArticleId IdType="pubmed">31287230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van der Heijde D.
How to read radiographs according to the Sharp/van Der Heijde method. J Rheumatol
1999;26:743–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10090194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van der Heijde DM, van Leeuwen MA, van Riel PL, et al. . 
Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum
1992;35:26–34. 10.1002/art.1780350105
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.1780350105</ArticleId>
            <ArticleId IdType="pubmed">1731813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woodworth T, Furst DE, Alten R, et al. . 
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the rheumatology common toxicity criteria v.2.0. J Rheumatol
2007;34:1401–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17552067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
NCI 
Common terminology criteria for adverse events (CTCAE) version 4.0
NIH publication; 2009.</Citation>
        </Reference>
        <Reference>
          <Citation>
van der Heijde D, Tanaka Y, Fleischmann R, et al. . 
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum
2013;65:559–70. 10.1002/art.37816
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.37816</ArticleId>
            <ArticleId IdType="pubmed">23348607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. . 
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (option study): a double-blind, placebo-controlled, randomised trial. The Lancet
2008;371:987–97. 10.1016/S0140-6736(08)60453-5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(08)60453-5</ArticleId>
            <ArticleId IdType="pubmed">18358926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taylor PC, Keystone EC, van der Heijde D, et al. . 
Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med
2017;376:652–62. 10.1056/NEJMoa1608345
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1608345</ArticleId>
            <ArticleId IdType="pubmed">28199814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Genovese MC, Kremer J, Zamani O, et al. . 
Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med
2016;374:1243–52. 10.1056/NEJMoa1507247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1507247</ArticleId>
            <ArticleId IdType="pubmed">27028914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Genovese MC, van Vollenhoven RF, Wilkinson B, et al. . 
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther
2016;18
10.1186/s13075-016-1049-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13075-016-1049-3</ArticleId>
            <ArticleId IdType="pmc">PMC4918072</ArticleId>
            <ArticleId IdType="pubmed">27334658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Winthrop KL, Yamanaka H, Valdez H, et al. . 
Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol
2014;66:2675–84. 10.1002/art.38745
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.38745</ArticleId>
            <ArticleId IdType="pmc">PMC4285807</ArticleId>
            <ArticleId IdType="pubmed">24943354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim SC, Schneeweiss S, Liu J. 
Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res
2013;65:1600–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4090802</ArticleId>
            <ArticleId IdType="pubmed">23666917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chung W-S, Peng C-L, Lin C-L, et al. . 
Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis
2014;73:1774–80. 10.1136/annrheumdis-2013-203380
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-203380</ArticleId>
            <ArticleId IdType="pubmed">23926057</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
